Table 3.

Association Between Dose of ACE Inhibitor Therapy Dispensed and the Outcomes During One Year of Follow-up for the 16,539 Older Adults Surviving 45 days Past a New Heart Failure Admission Between January 1, 1998, and December 31, 1999

	Hazard Ratio (CI)
Dose (Day 45)	Death	Death/Heart Failure Hospitalization	Death/All Hospitalization
None (N= 5,746)	1.12 (1.02 to 1.22)	1.08 (1.00 to 1.16)	1.04 (0.98 to 1.10)
Low *(N= 3,935)	1.00	1.00	1.00
Medium (N= 4,316)	0.94 (0.86 to 1.03)	0.95 (0.88 to 1.02)	0.95 (0.89 to 1.00)
High (N= 2,542)	0.76 (0.68 to 0.85)	0.87 (0.80 to 0.95)	0.87 (0.81 to 0.93)

Adjusted for age, gender, comorbidity, medical history (hyperkalemia, renal disease, hypotension, edema, diabetes, AMI), as well as concomitant use of other heart failure drug therapies (beta-blockers, angiotensin-receptor blockers, ASA, calcium channel blockers, spironolactone, potassium supplements, digoxin, and diuretics).

^*Reference category.

ACE, angiotensin-converting enzyme; CI, confidence interval; AMI, acute myocardial infarction; ASA, acetyl salicylic acid.